Figure 4
From: EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma
An increase in H3K27me3 levels caused by sorafenib in liver cancer cells. (A) Cells treated with sorafenib in varying concentration for 48 h were subject to Western blot analyses. The arrow indicates the cleaved form pf PARP. RI was shown as the means of three independent experiments. (B) Real-time PCR analyses of the UTX expression in cells treated with sorafenib for 48 h (Student’s t test, *p < 0.01, **p < 0.05) (C) Immunocytochemical analyses for phospho-EZH2 at serine 21 (Ser21) (red) and DAPI (blue) after treatment of Huh7 cells with sorafenib (5 μM) and regorafenib (5 μM) for 48 h. Scale bar = 50 µm. (D) Cells treated with sorafenib and GSK126 or UNC1999 were subjected to Western blot analyses.
